A Phase 1B, Randomized, Double-Blind, Placebo-controlled, ascending single dose study to evaluate the safety, tolerability and efficacy of SER-262 in adults with primary Clostridium Difficile Infection (C-Diff) to prevent recurrence.
Purpose: The purpose of this study is to see how safe and effective SER-262 is compared to a placebo, a capsule containing no active drug, in keeping Clostridium difficile infection (C-Diff) from coming back in people who have recovered from a first episode of C-Diff.
Sponsor: Seres Therapeutics, Inc.
Contact: Dr. Weinstock's study coordinator Kelly Moushey at Sundance Clinical Research: 314-567-3377.
Cisapride Motility Study
This is a compassionate medicine program for patients with either: severe acid reflux, gastroparesis, small intestinal pseudoobstruction, or constipation. Patients who have these conditions and have not responded to other available medicines are able to get this promotility medicine. The company pays for the medicine. The patients are responsible for the clinical follow up, blood tests and EKG tests during the years of treatment.
Clostridia difficile infection
Treatment to prevent recurrent infections is offered. Call 314-567-3377 to talk to the research coordinator.